Tag: Atherosclerosis

A recent study discovered an association between visceral and, to a lesser extent, hepatic fat with cardiovascular risk factors and carotid atherosclerosis. This association persists even after adjusting for cardiovascular risk factors [1]. Beyond BMI Body mass index (BMI) is a metric that compares height to total weight, including fat located under the skin (subcetaneous...

According to a study published by Cyclarity Therapeutics, its drug UDP-003 shows benefits in reversing the root cause of atherosclerotic plaques [1]. Fighting the root cause Many available medications address only disease symptoms in an effort to mitigate them. However, the real challenge is to identify the root cause of a problem and find ways...

Recently, Cyclarity Therapeutics announced the launch of a Phase 1 human clinical trial for a drug that aims to remove the arterial plaques that lead to heart attacks and strokes. Tackling the leading cause of death worldwide Cyclarity Therapeutics is working on a cost-effective small molecule drug aimed at eliminating arterial plaque, thus potentially addressing...

Cyclarity Therapeutics, a biotechnology company based at the Buck Institute in California, has launched its first human clinical trial. Its primary candidate cyclodextrin drug, UDP-003, focuses on 7-ketocholesterol, an oxidized cholesterol variant that builds up in cells as we age. Atherosclerosis involves the accumulation of plaque within arteries, and it primarily results from this oxidized...

A new study suggests that increased protein intake, specifically of the amino acid leucine, can exacerbate atherosclerosis by inhibiting autophagy in macrophages [1]. Protein: friend or foe? The protein we get from food is indispensable, as it allows us to produce our own proteins, but the ideal amount of dietary protein remains an open question....

Cyclarity Therapeutics is developing an affordable, plaque-busting small molecule that may be the cure for the world's number one killer: cardiovascular disease. With human trials planned for this year, we decided that it was time to catch up with Cyclarity and its CEO of Scientific Affairs, Dr. Matthew O’Connor, to see how things were going....